Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds increase insulin production and reduce glucagon

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising approaches for controlling blood sugar levels and may improve the lives of individuals living with diabetes. This novel class of dr